The authors concluded that carvedilol remained clinically efficacious in the COPERNICUS trial of patients with severe HF when additionally administered to background spironolactone in patients who were virtually all being treated with an angiotensin-converting enzyme inhibitor (or angiotensin II antagonist). This evidence concerns the gene AGT and hydrops fetalis.